Determining the Superiority of Vitrectomy vs Aflibercept for Treating Dense Diabetic Vitreous Hemorrhage: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

References

• Burton MJ, Ramke J, Marques AP, et al. The Lancet global health commission on global eye health: vision beyond 2020. Lancet Glob Health. 2021;9(4):e489–e551. doi:10.1016/S2214-109X(20)30488-5
   PubMed Web of Science ®Google Scholar
• Group ETDRSR. Fundus photographic risk factors for progression of diabetic retinopathy: ETDRS report number 12. Ophthalmology. 1991;98(5):823–833. doi:10.1016/S0161-6420(13)38014-2
   PubMed Web of Science ®Google Scholar
• Riaskoff S. Photocoagulation treatment of proliferative diabetic retinopathy. Ophthalmology. 1981;88(7):583–600.
   PubMedGoogle Scholar
• Lövestam‐Adrian M, Svendenius N, Agardh E. Contrast sensitivity and visual recovery time in diabetic patients treated with panretinal photocoagulation. Acta Ophthalmol Scand. 2000;78(6):672–676. doi:10.1034/j.1600-0420.2000.078006672.x
   PubMedGoogle Scholar
• Group ETDRSR. Early photocoagulation for diabetic retinopathy: ETDRS report number 9. Ophthalmology. 1991;98(5):766–785. doi:10.1016/S0161-6420(13)38011-7
   PubMed Web of Science ®Google Scholar
• Smiddy WE, Flynn HW Jr. Vitrectomy in the management of diabetic retinopathy. Surv Ophthalmol. 1999;43(6):491–507. doi:10.1016/s0039-6257(99)00036-3
   PubMed Web of Science ®Google Scholar
• Gong D, Hall N, Elze T, et al. Temporal trends in the treatment of proliferative diabetic retinopathy: an AAO IRIS® registry analysis. Ophthalmol Sci. 2021;1(3):100037. doi:10.1016/j.xops.2021.100037
   PubMedGoogle Scholar
• Papadopoulos N, Martin J, Ruan Q, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. 2012;15:171–185. doi:10.1007/s10456-011-9249-6
   PubMed Web of Science ®Google Scholar
• Stewart MW, Rosenfeld PJ. Predicted biological activity of intravitreal VEGF Trap. Br J Ophthalmol. 2008;92(5):667–668. doi:10.1136/bjo.2007.134874
   PubMed Web of Science ®Google Scholar
• Sivaprasad S, Prevost AT, Vasconcelos JC, et al. Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial. Lancet. 2017;389(10085):2193–2203.
   PubMed Web of Science ®Google Scholar
• Koshchynets O, Vadiuk R. Managing proliferative diabetic retinopathy in a patient with vitreous hemorrhage: a case report. Clinical Trials. 2022;8:11.
   Google Scholar
• Umanets N, Korol A, Vit V, Zavodnaya V, Pasyechnikova N. Peculiarities of vitrectomy and morphologic changes in the epiretinal membrane after intravitreal aflibercept in patients with severe proliferative diabetic retinopathy. Retin Cases Brief Rep. 2017;11(2):114–118. doi:10.1097/ICB.0000000000000306
   PubMedGoogle Scholar
• Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1–9. doi:10.1186/2046-4053-4-1
   PubMed Web of Science ®Google Scholar
• Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928–d5928. doi:10.1136/bmj.d5928
   PubMed Web of Science ®Google Scholar
• Mansour AM, Ashraf M, El Jawhari KM, et al. Intravitreal ziv-aflibercept in diabetic vitreous hemorrhage. Int J Retina Vitr. 2020;6(1):1–4. doi:10.1186/s40942-019-0204-9
   PubMedGoogle Scholar
• Maturi RK, Glassman AR, Josic K, et al. Effect of intravitreous anti–vascular endothelial growth factor vs sham treatment for prevention of vision-threatening complications of diabetic retinopathy: the protocol w randomized clinical trial. JAMA Ophthalmol. 2021;139(7):701–712. doi:10.1001/jamaophthalmol.2021.0606
   PubMed Web of Science ®Google Scholar
• Nicholson L, Crosby-Nwaobi R, Vasconcelos JC, et al. Mechanistic evaluation of panretinal photocoagulation versus aflibercept in proliferative diabetic retinopathy: CLARITY substudy. Invest Ophthalmol Vis Sci. 2018;59(10):4277–4284. doi:10.1167/iovs.17-23509
   PubMed Web of Science ®Google Scholar
• Antoszyk AN, Glassman AR, Beaulieu WT, et al. Effect of intravitreous aflibercept vs vitrectomy with panretinal photocoagulation on visual acuity in patients with vitreous hemorrhage from proliferative diabetic retinopathy: a randomized clinical trial. JAMA. 2020;324(23):2383–2395. doi:10.1001/jama.2020.23027
   PubMed Web of Science ®Google Scholar
• Abd Elhamid AH, Mohamed AAEA, Khattab AM. Intravitreal Aflibercept injection with Panretinal photocoagulation versus early Vitrectomy for diabetic vitreous hemorrhage: randomized clinical trial. BMC Ophthalmol. 2020;20(1):1–9. doi:10.1186/s12886-020-01401-4
   PubMed Web of Science ®Google Scholar
• Glassman AR, Beaulieu WT, Maguire MG, et al. Visual acuity, vitreous hemorrhage, and other ocular outcomes after vitrectomy vs aflibercept for vitreous hemorrhage due to diabetic retinopathy: a secondary analysis of a randomized clinical trial. JAMA Ophthalmol. 2021;139(7):725–733. doi:10.1001/jamaophthalmol.2021.1110
   PubMed Web of Science ®Google Scholar
• Salam A, Mathew R, Sivaprasad S. Treatment of proliferative diabetic retinopathy with anti‐VEGF agents. Acta Ophthalmol. 2011;89(5):405–411. doi:10.1111/j.1755-3768.2010.02079.x
   PubMed Web of Science ®Google Scholar
• Marolo P, Borrelli E, Gelormini F, et al. Retinal thickness deviation: a new OCT parameter for assessing diabetic macular edema. J Clin Med. 2023;12(12):3976. doi:10.3390/jcm12123976
   PubMed Web of Science ®Google Scholar
• Chen -Y-Y, Chang P-Y, Wang J-K. Intravitreal aflibercept for patients with diabetic macular edema refractory to bevacizumab or ranibizumab: analysis of response to aflibercept. Asia Pac J Ophthalmol. 2017;6(3):250–255. doi:10.22608/APO.2016186
   PubMed Web of Science ®Google Scholar
• Kim JH, Kim CG, Lee DW, et al. Intravitreal aflibercept for submacular hemorrhage secondary to neovascular age-related macular degeneration and polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol. 2020;258:107–116. doi:10.1007/s00417-019-04474-0
   PubMed Web of Science ®Google Scholar
• Weng S-W, Huang T-L, Chang P-Y. Intravitreal aflibercept for rubeosis iridis secondary to proliferative diabetic retinopathy. Acta Ophthalmol. 2015;30(4):201–203.
   Google Scholar
• Heier JS, Clark WL, Boyer DS, et al. Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study. Ophthalmology. 2014;121(7):1414–20. e1. doi:10.1016/j.ophtha.2014.01.027
   PubMed Web of Science ®Google Scholar
• Imrey PB. Limitations of meta-analyses of studies with high heterogeneity. JAMA Netw Open. 2020;3(1):e1919325–e. doi:10.1001/jamanetworkopen.2019.19325
   PubMed Web of Science ®Google Scholar
• Hsuan JD, Brown NA, Bron AJ, Patel CK, Rosen PH. Posterior subcapsular and nuclear cataract after vitrectomy. J Cataract Refract Surg. 2001;27(3):437–444. doi:10.1016/S0886-3350(00)00585-X
   PubMed Web of Science ®Google Scholar
• McLeod RS. Issues in surgical randomized controlled trials. World J Surg. 1999;23:1210–1214. doi:10.1007/s002689900649
   PubMed Web of Science ®Google Scholar
• Howard L, Thornicroft G. Patient preference randomised controlled trials in mental health research. Br J Psychiatry. 2006;188(4):303–304. doi:10.1192/bjp.188.4.303
   PubMedGoogle Scholar
• Song JW, Chung KC. Observational studies: cohort and case-control studies. Plast Reconstr Surg. 2010;126(6):2234. doi:10.1097/PRS.0b013e3181f44abc
   PubMed Web of Science ®Google Scholar